Rallybio Corp (RLYB) Stock Price & Analysis

Rallybio Corp (RLYB) rose 0.00% to USD 15.91 as of June 10, 2026 at 02:18 UTC, according to Nexqual real-time market data.

RLYB last closed at USD 15.91; the session ranged USD 15.8–16.5 on volume of 24,176 shares. Market capitalization is $92.28M, with a 52-week range of USD 2.4–17.57 (NCM). Source: Nexqual, June 10, 2026 at 02:18 UTC.

Key Statistics (as of June 10, 2026 at 02:18 UTC)

Technical Analysis (RLYB)

Nexqual's technical model rates RLYB "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:18 UTC.

Analyst Ratings (RLYB)

Wall Street analysts rate RLYB "None", per Nexqual as of June 10, 2026 at 02:18 UTC.

Earnings (RLYB)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 02:18 UTC.

Financials & Fundamentals (RLYB)

Source: Nexqual, June 10, 2026 at 02:18 UTC.

Financial Health Score (RLYB)

Nexqual rates Rallybio Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:18 UTC.

Ownership (RLYB)

Source: Nexqual, June 10, 2026 at 02:18 UTC.

Leadership (RLYB)

Rallybio Corp is led by Stephen Uden M.D., MBBS (age 67), Co-Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 02:18 UTC.

Major Backers & Investors (RLYB)

Notable institutional backers of Rallybio Corp include FMR, LLC, Viking Global, Cormorant Asset Management, LP, according to Nexqual as of June 10, 2026 at 02:18 UTC.

Active Investors

Source: Nexqual, June 10, 2026 at 02:18 UTC.

From Rallybio Corp's Latest SEC 10-K Filing (filed 2026-03-16)

Key Strengths & Strategy (as disclosed to the SEC)

• We utilize a multi-layered approach that includes acquiring intellectual property rights through purchase or exclusive license, filing and prosecuting U.S. and foreign patent applications directed to our own innovations, and developing and protecting proprietary know-how to maintain our competitive position.
• Government Regulation of Drug and Biological Products In the United States, the FDA regulates human drugs under the Federal Food, Drug, and Cosmetic Act, (the "FDCA"), and in the case of biologics, also under the Public Health Service Act (the "PHSA"), and their implementing regulations.
• Potential benefits of our approach We believe PTR represents an attractive development opportunity for RLYB116 for several reasons.
• However, direct oral anticoagulants are generally less effective in preventing recurrent thromboembolic events, most notably strokes. 4 T a b le of Contents Potential benefits of our approach We believe APS is an attractive indication to pursue as part of a comprehensive development strategy for two reasons.

Partnerships

• Concurrently with the execution and delivery of the Merger Agreement, certain investors entered into subscription agreements with Candid, pursuant to which such investors have agreed to purchase, immediately prior to the Merger, shares of Candid common stock representing an aggregate commitment of approximately $505.5 million in the concurrent financing (the "Concurrent Financing").
• Our Strategy In 2025, the Company made a decision to evaluate strategic alternatives, with a goal of enhancing long term shareholder value that culminated with the signing of the Merger Agreement with Candid, a clinical-stage biotechnology company advancing a leading portfolio of TCE therapeutics for autoimmune diseases on March 1, 2026.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:18 UTC. This page is informational and not investment advice.